TW202332446A - 保存效果或光穩定性經改善之眼科藥用組成物 - Google Patents

保存效果或光穩定性經改善之眼科藥用組成物 Download PDF

Info

Publication number
TW202332446A
TW202332446A TW112113506A TW112113506A TW202332446A TW 202332446 A TW202332446 A TW 202332446A TW 112113506 A TW112113506 A TW 112113506A TW 112113506 A TW112113506 A TW 112113506A TW 202332446 A TW202332446 A TW 202332446A
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
acceptable salt
carteolol
pharmaceutical composition
items
Prior art date
Application number
TW112113506A
Other languages
English (en)
Chinese (zh)
Inventor
長濱良治
近藤文雄
大八木優
平田雄樹
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202332446A publication Critical patent/TW202332446A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112113506A 2016-08-23 2017-08-22 保存效果或光穩定性經改善之眼科藥用組成物 TW202332446A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016-162611 2016-08-23
JP2016162611 2016-08-23

Publications (1)

Publication Number Publication Date
TW202332446A true TW202332446A (zh) 2023-08-16

Family

ID=59812062

Family Applications (4)

Application Number Title Priority Date Filing Date
TW112113506A TW202332446A (zh) 2016-08-23 2017-08-22 保存效果或光穩定性經改善之眼科藥用組成物
TW110149715A TWI828025B (zh) 2016-08-23 2017-08-22 保存效果或光穩定性經改善之眼科藥用組成物
TW106128430A TWI814709B (zh) 2016-08-23 2017-08-22 保存效果或光穩定性經改善之眼科藥用組成物
TW113131450A TW202513068A (zh) 2016-08-23 2017-08-22 保存效果或光穩定性經改善之眼科藥用組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW110149715A TWI828025B (zh) 2016-08-23 2017-08-22 保存效果或光穩定性經改善之眼科藥用組成物
TW106128430A TWI814709B (zh) 2016-08-23 2017-08-22 保存效果或光穩定性經改善之眼科藥用組成物
TW113131450A TW202513068A (zh) 2016-08-23 2017-08-22 保存效果或光穩定性經改善之眼科藥用組成物

Country Status (4)

Country Link
JP (3) JP7123034B2 (enExample)
CN (3) CN115444849B (enExample)
TW (4) TW202332446A (enExample)
WO (1) WO2018038102A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022131565A (ja) * 2021-02-26 2022-09-07 ロート製薬株式会社 水性医薬組成物
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135887A (ja) * 1987-11-20 1989-05-29 Lion Corp 紫外線吸収剤組成物
FR2777189B1 (fr) * 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
JP4361294B2 (ja) * 2003-02-25 2009-11-11 ロート製薬株式会社 ケトチフェン含有組成物
JP5711957B2 (ja) * 2003-09-30 2015-05-07 ロート製薬株式会社 透明包装体入りトラニラスト含有医薬製剤
KR20060102282A (ko) * 2005-03-22 2006-09-27 테이카 세이야쿠 가부시키가이샤 점안제
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
JP5661456B2 (ja) * 2008-04-23 2015-01-28 大塚製薬株式会社 点眼剤及び使用方法
CN101461780A (zh) 2009-01-06 2009-06-24 河北科技大学 不含抑菌剂的盐酸卡替洛尔滴眼液及其制备方法
TW201109325A (en) 2009-07-30 2011-03-16 Wakamoto Pharma Co Ltd Aqueous composition for eye drops
CN103079595B (zh) * 2010-08-27 2015-11-25 若素制药株式会社 滴眼用水性组合物
CN104136019A (zh) * 2012-02-27 2014-11-05 日本乐敦制药株式会社 眼科用组合物试剂盒

Also Published As

Publication number Publication date
TW202513068A (zh) 2025-04-01
TWI814709B (zh) 2023-09-11
TW201811331A (zh) 2018-04-01
CN115444849A (zh) 2022-12-09
CN115444849B (zh) 2025-07-01
CN115463130A (zh) 2022-12-13
JP2022172124A (ja) 2022-11-15
JP7123034B2 (ja) 2022-08-22
JP2024112862A (ja) 2024-08-21
JP2019526549A (ja) 2019-09-19
TW202231276A (zh) 2022-08-16
CN109641059A (zh) 2019-04-16
CN109641059B (zh) 2022-08-30
TWI828025B (zh) 2024-01-01
WO2018038102A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
CN102958509B (zh) 用于不含防腐剂的非粘性前列腺素类溶液的聚合物给药系统
JP6527341B2 (ja) ポビドンヨード、眼科用組成物のための新規代替保存剤
TWI489997B (zh) 含有硼酸－多元醇錯合物之水性藥學組成物
JP5901087B2 (ja) 点眼用水性組成物
MX2013010101A (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
CA2725523A1 (en) Self-preserved emulsions
JP2024112862A (ja) 保存効力又は光安定性が改善された点眼用医薬組成物
RU2745317C2 (ru) Фармацевтическая композиция, включающая дорзоламид и бримонидин
US9561280B2 (en) Aqueous liquid bromfenac composition having preservative efficacy
RU2745617C2 (ru) Антисептическое средство, включающее меглюмин или его соль
HK40082707A (en) Ophthalmic pharmaceutical composition with improved preservative effectiveness or light stability
HK40082706A (zh) 具有改善的防腐效力或光稳定性的眼科药物组合物
UA115454C2 (uk) Композиція фінафлоксацину у вигляді суспензії
CN102497854A (zh) 含有作为防腐剂的丙酸衍生物的眼用液体药物组合物
TW202404569A (zh) 含有賽佩普斯特(Sepetaprost)之眼科用組合物
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
JP2022123792A (ja) 水性医薬組成物